COMP <GO>
ETON vs UNH // ALTMAN Z-SCORE & DEBT/EQUITY
Eton Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ETON 2
— UNH 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ETON
LAST: $50.81 (-2.63%) • MKT CAP: $1.45B
balance-sheet
13.37
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
balance-sheet
3.09
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ETON VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ETON | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.50% | 88.31% | -34.81 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -0.90% | 12.38% | -13.28 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.66% | 6.25% | -5.59 | UNH | /fcf-yield <GO> |
| Operating Margin | -1.10% | 5.32% | -6.42 | UNH | /operating-margins <GO> |
| Net Profit Margin | -5.80% | 3.53% | -9.33 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 104.90% | 3.33% | +101.57 | ETON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 13.37 | 3.09 | +10.28 | ETON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.0 | 55.1 | -11.10 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.45B | $359.43B | -$357.98B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ETON REV | UNH REV | ETON GROSS % | UNH GROSS % | ETON FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $80.0M | $447.57B | 53.5% | 88.7% | $10.2M | $16.07B |
| FY 2024 | $39.0M | $400.28B | 60.0% | 88.3% | $943.0K | $20.70B |
| FY 2023 | $31.6M | $371.62B | — | 89.6% | $6.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ETON // BETA —
UNH // BETA 0.33